Compugen Reports Fourth Quarter and Full Year 2024 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Rodman & Renshaw Reiterates Buy Rating on Compugen (CGEN)
March 4, 2025 10:26 AM ESTRodman & Renshaw analyst Tony Blair reiterated a Buy rating and $4.00 price target on Compugen (NASDAQ: CGEN).
The analyst comments "This morning, before the market opened, Compugen Ltd. (CGEN; Buy) released its business updates for 4Q24. The company reported an ending cash balance of $103.3 million for the quarter, which is expected to provide funding into 2027. CGEN remains on track to initiate a randomized adaptive platform trial in 2Q25 to... More
